Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

276.02USD
23 Jan 2017
Change (% chg)

$-4.64 (-1.65%)
Prev Close
$280.66
Open
$280.35
Day's High
$282.72
Day's Low
$275.49
Volume
1,858,013
Avg. Vol
1,639,103
52-wk High
$333.65
52-wk Low
$223.02

BIIB.O

Chart for BIIB.O

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $61,064.45
Shares Outstanding(Mil.): 217.57
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 15.87 29.51 30.38
EPS (TTM): 17.69 -- --
ROI: 20.56 15.44 14.86
ROE: 34.25 16.62 16.28

BRIEF-Ewopharma partners with Biogen to commercialise Benepali and Flixabi

* Ewopharma partners with biogen to commercialise benepali and flixabi in central eastern europe

8:58am EST

Biogen to pay Forward Pharma $1.25 bln to protect MS drug

Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion to license the Danish company's patents covering multiple sclerosis drugs, providing Biogen an insurance policy on future sales of Tecfidera, its blockbuster oral treatment for the disease.

Jan 17 2017

Biogen to pay Forward Pharma $1.25 billion to protect MS drug

Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion to license the Danish company's patents covering multiple sclerosis drugs, providing Biogen an insurance policy on future sales of Tecfidera, its blockbuster oral treatment for the disease.

Jan 17 2017

UPDATE 2-Biogen to pay Forward Pharma $1.25 bln to protect MS drug

Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion to license the Danish company's patents covering multiple sclerosis drugs, providing Biogen an insurance policy on future sales of Tecfidera, its blockbuster oral treatment for the disease.

Jan 17 2017

BRIEF-FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN

* FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN

Jan 17 2017

Biogen in $1.25 bln deal with Forward Pharma to protect MS drug

Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera.

Jan 17 2017

BRIEF-Biogen, Forward Pharma to enter into settlement and license agreement

* Biogen and Forward Pharma agree to enter into settlement and license agreement

Jan 17 2017

BRIEF-Biogen spin-off Bioverativ commences when-issued trading of common stock

* Biogen spin-off Bioverativ commences when-issued trading of common stock

Jan 12 2017

FDA approves Biogen drug for lead genetic cause of infant death

The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants.

Dec 23 2016

Investors see Biogen CEO choice as friendly to potential takeover

NEW YORK The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.

Dec 21 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $113.91 -0.24
Pfizer Inc. (PFE.N) $31.46 -0.31
Novartis AG (NOVN.S) CHF70.05 -0.85
Merck & Co., Inc. (MRK.N) $61.81 -0.72
Roche Holding Ltd. (ROG.S) CHF232.20 -1.30
Roche Holding Ltd. (RO.S) CHF234.80 -1.30
Bayer AG (BAYGn.DE) €101.05 -1.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.84 -0.78
GlaxoSmithKline plc (GSK.L) 1,527.00 -19.50

Earnings vs. Estimates